BRANDON AIMAN: Open Payments
NPI 1831124999 · ANDERSON, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,082 in 103 payments from 21 companies in 2025. Trend: 2023 $2,048 · 2024 $2,123 · 2025 $2,082
Food & beverage: $2,082
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 17 | $400 |
| GlaxoSmithKline, LLC. | 23 | $389 |
| GENZYME CORPORATION | 8 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $152 |
| Insmed, Inc. | 6 | $115 |
| Verona Pharma, Inc. | 4 | $97 |
| Actelion Pharmaceuticals US, Inc. | 4 | $81 |
| Regeneron Healthcare Solutions, Inc. | 3 | $78 |
| Grifols USA, LLC | 3 | $76 |
| Mallinckrodt Hospital Products Inc. | 3 | $71 |
Products named: NUCALA, DUPIXENT, FASENRA, TEZSPIRE, GLASSIA, TRELEGY ELLIPTA, Arikayce, Ohtuvayre.
Industry payments across IN — which companies pay providers there.
